Abpro Holdings, Inc. (ABP) Earnings Signals & AI Vibe Check

Latest Filing: 10-Q  |  Filed May 20, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Abpro Holdings, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, Abpro Holdings, Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Continuing Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Abpro Holdings, Inc. actually do?
Answer:
Abpro Holdings, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for severe and life-threatening diseases, primarily in immuno-oncology, ophthalmology, and infectious disease. The company leverages its proprietary DiversImmune(R) discovery and MultiMabTM engineering platforms to create novel multi-specific antibody constructs, including its lead TetraBi antibody format. Its lead product candidates are ABP-102, a T-cell engager targeting HER2 and CD3 for HER2+ solid tumors, and ABP-201, a ligand trap targeting VEGF and ANG-2 for ophthalmic vascular diseases. Abpro has established strategic partnerships for the development and commercialization of these candidates, including a significant collaboration with Celltrion for ABP-102.
Question:
What are Abpro Holdings, Inc.'s revenue drivers?
Answer:
The company's revenue drivers are primarily milestone payments and potential royalties from its collaboration and license agreements with partners for the development and commercialization of its antibody therapeutics.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required